A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.

@article{Rao2008ASO,
  title={A study of the pharmacokinetic interaction of istradefylline, a novel therapeutic for Parkinson's disease, and atorvastatin.},
  author={Niranjan Sathyanarayana Rao and Barry Dvorchik and Norman Sussman and Hong-yun Wang and Keisuke Yamamoto and Akihisa Mori and Tatsuo Uchimura and Philip Chaikin},
  journal={Journal of clinical pharmacology},
  year={2008},
  volume={48 9},
  pages={
          1092-8
        }
}
The effect of steady-state istradefylline, an agent for Parkinson's disease with P-glycoprotein and CYP3A inhibitory activity, on the pharmacokinetics of atorvastatin and its metabolites was evaluated in healthy volunteers. A single 40-mg dose of atorvastatin was administered to 20 subjects. After a 4-day washout, subjects received a single 40-mg atorvastatin dose following 40 mg istradefylline (n=16) or placebo (n=4) daily for 14 days. Plasma samples collected for 96 hours after atorvastatin… CONTINUE READING
BETA

Topics from this paper.

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…